Nasdaq:OKYO

Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain componentTop-line data from trial anticipated in Q4, 2023 LONDON and NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma…

<!-- Name:DistributionId Value:8837000 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8829334 --> <!-- Name:EnableQuoteCarouselOnPnr Value:True --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8823999 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8789187 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8787183 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

<!-- Name:DistributionId Value:8777834 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet…

-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- -Phase 2 study expected to open to enrollment in the first quarter 2023- LONDON and NEW…

LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet…